Tarsus Pharmaceuticals Inc (NAS:TARS)
$ 32.96 -1.71 (-4.92%) Market Cap: 1.25 Bil Enterprise Value: 977.28 Mil PE Ratio: 0 PB Ratio: 4.52 GF Score: 51/100

Q3 2023 Tarsus Pharmaceuticals Inc Earnings Call Transcript

Nov 09, 2023 / 09:30PM GMT
Release Date Price: $15.57 (-5.86%)
Operator

Good afternoon. And welcome to the Tarsus Pharmaceuticals third quarter 2023 financial results conference call. As a reminder, this call is being recorded. At this time, I'd like to turn the call over to David Nakasone, Head of Investor Relations, to lead off the call. Please begin.

David Nakasone
Tarsus Pharmaceuticals, Inc. - Head of Investor Relations

Thank you. Before we begin, I encourage everyone to go to the Investors section of the Tarsus website to view the earnings release and related financial tables we will be discussing today. Joining me on the call this afternoon are: Bobak Azamian, our Chief Executive Officer and Chairman; Aziz Mottiwala, our Chief Commercial Officer; and Jeff Farrow, our Chief Financial Officer and Chief Strategy Officer.

I'd like to draw your attention to Slide 3, which contains our forward-looking statements. During this call, we will be making forward-looking language statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties. And our actual

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot